Dan Leonard
Stock Analyst at UBS
(1.98)
# 2,864
Out of 4,784 analysts
278
Total ratings
53.95%
Success rate
-6.25%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $20 → $14 | $9.16 | +52.84% | 4 | Feb 13, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $260 → $255 | $177.39 | +43.75% | 13 | Feb 7, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $700 → $715 | $500.16 | +42.95% | 14 | Jan 31, 2025 | |
| AVTR Avantor | Downgrades: Neutral | $29 → $25 | $16.18 | +54.51% | 7 | Jan 17, 2025 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | $250 → $185 | $155.55 | +18.93% | 6 | Jan 17, 2025 | |
| BRKR Bruker | Assumes: Neutral | $102 → $66 | $42.08 | +56.84% | 10 | Dec 10, 2024 | |
| DHR Danaher | Maintains: Buy | $309 → $305 | $205.85 | +48.17% | 16 | Oct 23, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $7 → $9 | $6.09 | +47.78% | 2 | Oct 18, 2024 | |
| MEDP Medpace Holdings | Downgrades: Neutral | $420 → $350 | $312.36 | +12.05% | 1 | Sep 27, 2024 | |
| CERT Certara | Upgrades: Buy | $16 | $9.91 | +61.45% | 9 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $43.14 | -7.28% | 8 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $420 → $385 | $243.00 | +58.44% | 19 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $420 → $385 | $265.82 | +44.83% | 19 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $105 → $125 | $105.62 | +18.35% | 1 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $58.73 | +36.22% | 10 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $17.05 | +105.28% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $116.69 | +28.55% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $80.00 | +150.00% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.36 | +366.10% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $143.94 | -51.37% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $43.66 | +106.14% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $7.67 | -8.74% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $362.16 | -4.74% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $179.07 | +45.19% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $167.33 | -13.34% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $61.32 | +46.77% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $39.85 | +59.72% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $230.02 | +47.81% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $20.29 | +18.28% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,350 → $1,500 | $1,177.09 | +27.43% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $8.88 | +294.14% | 12 | Aug 14, 2019 |
10x Genomics
Feb 13, 2025
Maintains: Neutral
Price Target: $20 → $14
Current: $9.16
Upside: +52.84%
IQVIA Holdings
Feb 7, 2025
Maintains: Buy
Price Target: $260 → $255
Current: $177.39
Upside: +43.75%
Thermo Fisher Scientific
Jan 31, 2025
Maintains: Buy
Price Target: $700 → $715
Current: $500.16
Upside: +42.95%
Avantor
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $16.18
Upside: +54.51%
Charles River Laboratories International
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $155.55
Upside: +18.93%
Bruker
Dec 10, 2024
Assumes: Neutral
Price Target: $102 → $66
Current: $42.08
Upside: +56.84%
Danaher
Oct 23, 2024
Maintains: Buy
Price Target: $309 → $305
Current: $205.85
Upside: +48.17%
Cryoport
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $6.09
Upside: +47.78%
Medpace Holdings
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $312.36
Upside: +12.05%
Certara
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $9.91
Upside: +61.45%
Aug 21, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $43.14
Upside: -7.28%
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $243.00
Upside: +58.44%
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $265.82
Upside: +44.83%
Jan 16, 2024
Downgrades: Neutral
Price Target: $105 → $125
Current: $105.62
Upside: +18.35%
Dec 7, 2023
Initiates: Buy
Price Target: $80
Current: $58.73
Upside: +36.22%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $17.05
Upside: +105.28%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $116.69
Upside: +28.55%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $80.00
Upside: +150.00%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.36
Upside: +366.10%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $143.94
Upside: -51.37%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $43.66
Upside: +106.14%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $7.67
Upside: -8.74%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $362.16
Upside: -4.74%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $179.07
Upside: +45.19%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $167.33
Upside: -13.34%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $61.32
Upside: +46.77%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $39.85
Upside: +59.72%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $230.02
Upside: +47.81%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $20.29
Upside: +18.28%
Jul 30, 2021
Maintains: Equal-Weight
Price Target: $1,350 → $1,500
Current: $1,177.09
Upside: +27.43%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $8.88
Upside: +294.14%